Group 1 - The core viewpoint of the article highlights the recent stock performance of LianKang Biotechnology Group, which experienced a 5.0% decline, trading at 0.152 yuan per share with a transaction volume of 10.5667 million yuan as of 14:59 on August 12 [1] - LianKang Biotechnology Group focuses on four strategic areas: biopharmaceutical innovation, high-value generic drugs, new materials for medical aesthetics, and CMO (Contract Manufacturing Organization) [1] - The company aims to meet the growing demand for quality healthcare solutions in China, driven by aging population and population growth trends [1] Group 2 - As of the 2024 annual report, LianKang Biotechnology Group reported total revenue of 512 million yuan and a net profit of 76.652 million yuan [2]
联康生物科技集团(00690)下跌5.0%，报0.152元/股